Nova Eye Medical (EYE) Discussion, page-953

Well then if that's the case, the "on the ground information" must be very good then as the price is significantly higher than the cap raise price and there has been more volume traded than ever before (especially on green days).

I personally think the share price movements are random and therefore there is no point in watching them, but it's up to you of course if you'd prefer to focus on something that is irrelevant to the company in which we are invested in. I'd rather focus on what information we can find related to the actually business activities of EYE.

Also it's not the company downplaying the Medicare proposal, it is literally the whole industry. If it was a serious threat there would be talk all over LinkedIn and within ophthalmology media outlets, yet there is nothing at all (despite the proposals being old already). The only change we have seen recently to medicare is a very positive expansion in coverage for canaloplasty by Cigna. I can't see the payers expanding coverage and then taking it away within the same quarter, can you?

Who knows though, but we're invested in a $50m market cap (revenue generating) company so I'd say the downside risks are very well priced in